COSA 2020: First-Line Ribociclib Shown to Be Safe and Tolerable in Advanced Breast Cancer
Ribociclib endocrine therapy was well tolerated in a real-world setting.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.